Neither will we.

Inflammatory bowel diseases (IBD) affect 10 million people worldwide.1 In spite of significant scientific progress in the understanding of chronic inflammatory diseases, many patients continue to face challenges controlling their disease.2 At Gilead, we are committed to working with you to help address these challenges and, ultimately, to improve the lives of patients living with IBD.

Get the latest IBD updates from Gilead.

References : 1. European Federation of Crohn’s & Ulcerative Colitis Associations. http://www.efcca.org/sites/default/files/worldibddayreport_2018web.pdf. Accessed April 1, 2020. 2. Crohn’s & Colitis Foundation of America; 2014. https://site.crohnscolitisfoundation.org/assets/pdfs/ibdfactbook.pdf. Accessed April 1, 2020.

GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies.
© 2020 Gilead Sciences, Inc. All rights reserved. UNBP5968 10/20